PURPOSE: G17DT is a gastrin immunogen, raising antibodies that blockade gastrin-stimulated growth. The aim of the study was to characterise antibody response and assess safety and tolerability of G17DT given to patients with gastric cancer. EXPERIMENTAL DESIGN: G17DT was administered to 52 patients with gastric adenocarcinoma at weeks 0, 2 and 6 by intramuscular injection at doses of 10, 100 and 250 microg. Antibody levels were measured by an ELISA assay. A radioligand displacement assay determined the ability of G17DT-immunised patients' sera to inhibit binding of 125IG17 to cholecystokinin (CCK)-2 receptors. RESULTS: By week 12 of the study, 6/12 evaluable stage I-III patients achieved an antibody response in the 10 microg group, 7/11 in the 100 microg group, and 11/12 in the 250 microg group. Stage IV patients dosed at 250 microg achieved a similar response rate to stage I-III patients dosed at 10 or 100 microg. G17DT was well tolerated in 47/52 patients. Two patients suffered significant adverse reactions including injection site pain and abscess. G17DT antibodies displaced iodinated gastrin from CCK-2 receptors, with the level of displacement correlating with antibody titre. CONCLUSIONS: G17DT immunisation is a well-tolerated method of raising functional antibodies to 17 amino acid gastrin forms in patients with gastric carcinomas.
PURPOSE: G17DT is a gastrin immunogen, raising antibodies that blockade gastrin-stimulated growth. The aim of the study was to characterise antibody response and assess safety and tolerability of G17DT given to patients with gastric cancer. EXPERIMENTAL DESIGN: G17DT was administered to 52 patients with gastric adenocarcinoma at weeks 0, 2 and 6 by intramuscular injection at doses of 10, 100 and 250 microg. Antibody levels were measured by an ELISA assay. A radioligand displacement assay determined the ability of G17DT-immunised patients' sera to inhibit binding of 125IG17 to cholecystokinin (CCK)-2 receptors. RESULTS: By week 12 of the study, 6/12 evaluable stage I-III patients achieved an antibody response in the 10 microg group, 7/11 in the 100 microg group, and 11/12 in the 250 microg group. Stage IV patients dosed at 250 microg achieved a similar response rate to stage I-III patients dosed at 10 or 100 microg. G17DT was well tolerated in 47/52 patients. Two patients suffered significant adverse reactions including injection site pain and abscess. G17DT antibodies displaced iodinated gastrin from CCK-2 receptors, with the level of displacement correlating with antibody titre. CONCLUSIONS: G17DT immunisation is a well-tolerated method of raising functional antibodies to 17 amino acid gastrin forms in patients with gastric carcinomas.
Authors: Rodrigo Barderas; Johan Desmet; Peter Timmerman; Rob Meloen; J Ignacio Casal Journal: Proc Natl Acad Sci U S A Date: 2008-06-23 Impact factor: 11.205
Authors: Li Zhang; Pilar Londono; Liping Yu; Stephen Grimes; Peter Blackburn; Peter Gottlieb; George S Eisenbarth Journal: Autoimmunity Date: 2014-05-01 Impact factor: 2.815
Authors: Bin Liu; Jeffrey L Frost; Jing Sun; Hongjun Fu; Stephen Grimes; Peter Blackburn; Cynthia A Lemere Journal: J Neurosci Date: 2013-04-17 Impact factor: 6.167
Authors: Peter Timmerman; Rodrigo Barderas; Johan Desmet; Danièle Altschuh; Susana Shochat; Martine J Hollestelle; Jo W M Höppener; Alberto Monasterio; J Ignacio Casal; Rob H Meloen Journal: J Biol Chem Date: 2009-10-06 Impact factor: 5.157
Authors: Natasja K van den Engel; Dominik Rüttinger; Margareta Rusan; Robert Kammerer; Wolfgang Zimmermann; Rudolf A Hatz; Hauke Winter Journal: J Transl Med Date: 2011-08-22 Impact factor: 5.531